Business Context and Reporting Period
This Form 8-K was filed by Manhattan Pharmaceuticals, Inc. (noted as TG Therapeutics, Inc. in metadata) on April 8, 2010, reporting the final closing of a private placement transaction and the conversion of a senior subordinated convertible debenture.
Key Financial Metrics
- Net Proceeds: Approximately $51,700 received from the final closing of the private placement.
- Units Sold (Final Closing): 2.4 Units sold to three additional accredited investors.
- Unit Price: $25,000 per Unit.
- Transaction Costs: $8,300 paid in commissions and expense allowances to National Securities Corporation.
- Debt Conversion: A $400,000 12% OID Senior Subordinated Convertible Debenture, plus $21,886 in accrued interest, was converted into 16.88 Units.
- Placement Agent Compensation: Issuance of a warrant to purchase 12,857 shares of Common Stock at an exercise price of $0.08 per share.
Material Changes
The filing details the completion of a financing round previously initiated on March 2, 2010. The material change involves the issuance of equity and warrants to new investors and the extinguishment of $421,886 in debt obligations (principal and accrued interest) through conversion into equity units.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, revenue outlook, or management commentary regarding future operations. The primary risk disclosed relates to the liquidity of the securities; the Shares, Warrants, and shares issuable upon exercise are non-transferable absent an effective registration statement or available exemption, and all certificates bear a restrictive legend.
Investor Verification Checklist
- Verify the total aggregate number of Units sold across both the March 2 and April 8 closings to assess total dilution.
- Confirm the current cash balance post-transaction to evaluate runway given the small net proceeds ($51,700) from the final closing.
- Review the terms of the 12% OID Senior Subordinated Convertible Debenture to understand the conversion mechanics and remaining debt obligations.
- Check for any subsequent filings regarding the registration of the restricted securities to determine when they may become tradable.